101 related articles for article (PubMed ID: 23292484)
41. [Clinicopathological characteristics and prognostic significance of young patients with triple-negative breast cancer].
Zhang P; Xu BH; Ma F; Li Q
Zhonghua Zhong Liu Za Zhi; 2010 Feb; 32(2):128-31. PubMed ID: 20403244
[TBL] [Abstract][Full Text] [Related]
42. Predictors of locoregional outcome in patients receiving neoadjuvant therapy and postmastectomy radiation.
Wright JL; Takita C; Reis IM; Zhao W; Saigal K; Wolfson A; Markoe A; Moller M; Hurley J
Cancer; 2013 Jan; 119(1):16-25. PubMed ID: 22736498
[TBL] [Abstract][Full Text] [Related]
43. Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer.
Kiess AP; McArthur HL; Mahoney K; Patil S; Morris PG; Ho A; Hudis CA; McCormick B
Cancer; 2012 Apr; 118(8):1982-8. PubMed ID: 21887681
[TBL] [Abstract][Full Text] [Related]
44. Tumor characteristics and recurrence patterns in triple negative breast cancer: a comparison between younger (<65) and elderly (≥65) patients.
Königsberg R; Pfeiler G; Klement T; Hammerschmid N; Brunner A; Zeillinger R; Singer C; Dittrich C
Eur J Cancer; 2012 Nov; 48(16):2962-8. PubMed ID: 22647688
[TBL] [Abstract][Full Text] [Related]
45. Outcome after breast conservation treatment with radiation for women with triple-negative early-stage invasive breast carcinoma.
Solin LJ; Hwang WT; Vapiwala N
Clin Breast Cancer; 2009 May; 9(2):96-100. PubMed ID: 19433390
[TBL] [Abstract][Full Text] [Related]
46. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
[TBL] [Abstract][Full Text] [Related]
47. Current treatment options in triple negative breast cancer.
Rodler E; Korde L; Gralow J
Breast Dis; 2010; 32(1-2):99-122. PubMed ID: 21778572
[TBL] [Abstract][Full Text] [Related]
48. Young age is associated with ipsilateral breast tumor recurrence after breast conserving surgery and radiation therapy in patients with HER2-positive/ER-negative subtype.
Kim HJ; Han W; Yi OV; Shin HC; Ahn SK; Koh BS; Moon HG; You JH; Son BH; Ahn SH; Noh DY
Breast Cancer Res Treat; 2011 Nov; 130(2):499-505. PubMed ID: 21853352
[TBL] [Abstract][Full Text] [Related]
49. Magnetic resonance (MR) features in triple negative breast cancer (TNBC) vs receptor positive cancer (nTNBC).
Angelini G; Marini C; Iacconi C; Mazzotta D; Moretti M; Picano E; Morganti R
Clin Imaging; 2018; 49():12-16. PubMed ID: 29120811
[TBL] [Abstract][Full Text] [Related]
50. Breast cancer subtypes and outcome after local and regional relapse.
Montagna E; Bagnardi V; Rotmensz N; Viale G; Renne G; Cancello G; Balduzzi A; Scarano E; Veronesi P; Luini A; Zurrida S; Monti S; Mastropasqua MG; Bottiglieri L; Goldhirsch A; Colleoni M
Ann Oncol; 2012 Feb; 23(2):324-31. PubMed ID: 21525402
[TBL] [Abstract][Full Text] [Related]
51. Locoregional treatments for triple-negative breast cancer.
Eiermann W; Vallis KA
Ann Oncol; 2012 Aug; 23 Suppl 6():vi30-4. PubMed ID: 23012299
[TBL] [Abstract][Full Text] [Related]
52. Delays in time to primary treatment after a diagnosis of breast cancer: does it impact survival?
Mujar M; Dahlui M; Yip CH; Taib NA
Prev Med; 2013 Mar; 56(3-4):222-4. PubMed ID: 23234860
[TBL] [Abstract][Full Text] [Related]
53. Survival after locoregional recurrence or second primary breast cancer: impact of the disease-free interval.
Witteveen A; Kwast AB; Sonke GS; IJzerman MJ; Siesling S
PLoS One; 2015; 10(4):e0120832. PubMed ID: 25861031
[TBL] [Abstract][Full Text] [Related]
54. Locoregional recurrence in triple negative breast cancer: past, present, and future.
Tran J; Thaper A; Lopetegui-Lia N; Ali A
Expert Rev Anticancer Ther; 2023; 23(10):1085-1093. PubMed ID: 37750222
[TBL] [Abstract][Full Text] [Related]
55. Better Overall Survival for Breast Cancer Patients by Adding Breast Ultrasound to Follow-Up Examinations for Early Detection of Locoregional Recurrence-A Survival Impact Study.
Tsai WC; Wei HK; Hung CF; Kwang-Jane Lin C; Hung-Chun Cheng S; Chen CM; Wang YA
Ultrasound Med Biol; 2016 Sep; 42(9):2058-64. PubMed ID: 27184247
[TBL] [Abstract][Full Text] [Related]
56. Effect on survival of delays in referral of patients with breast-cancer symptoms: a retrospective analysis.
Sainsbury R; Johnston C; Haward B
Lancet; 1999 Apr; 353(9159):1132-5. PubMed ID: 10209976
[TBL] [Abstract][Full Text] [Related]
57. A semiparametric approach for the two-sample comparison of survival times with long-term survivors.
Broët P; De Rycke Y; Tubert-Bitter P; Lellouch J; Asselain B; Moreau T
Biometrics; 2001 Sep; 57(3):844-52. PubMed ID: 11550936
[TBL] [Abstract][Full Text] [Related]
58. Breast Cancer Treatment Delay in SafetyNet Health Systems, Houston Versus Southeast Brazil.
Shafaee MN; Silva LR; Ramalho S; Doria MT; De Andrade Natal R; Cabello V; Cons L; Pavanello M; Zeferino LC; Mano MS; Linck RDM; Batista LS; Pedro EP; De Paula BH; Zuca-Matthes G; Podany E; Makawita S; Ann Stewart K; Tsavachidis S; Tamimi R; Bondy M; Debord L; Ellis M; Bines J; Cabello C
Oncologist; 2022 May; 27(5):344-351. PubMed ID: 35348756
[TBL] [Abstract][Full Text] [Related]
59. Association of patient factors with time to treatment for breast cancer.
Valente S; Al-Hilli Z; Liu Y; Greve N; Tu C; Grobmyer SR
Breast J; 2020 Oct; 26(10):1995-2001. PubMed ID: 32924203
[TBL] [Abstract][Full Text] [Related]
60. Factors Influencing Total Delay of Breast Cancer in Northeast of China.
Ren S; Zhang Y; Qin P; Wang J
Front Oncol; 2022; 12():841438. PubMed ID: 35311134
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
